Business · Companies · 3 hrs ago
Rezera files for IPO to fund NLRP3 research
Biotech company Rezera has filed for an initial public offering, or IPO.
The company rebranded from NodThera earlier this year.
It plans to use the offering to support its NLRP3 work, which it has pursued for a decade.
The research includes work related to peripheral artery disease, a condition affecting blood flow in the limbs.
The filing is intended to help Rezera bolster its research efforts.
Rezera has entered the queue for an IPO, but no further details about the offering are given.
Rezera has entered the queue for an initial public offering to support its NLRP3 research.
The biotech’s work has focused on NLRP3 for a decade.
Its research is aimed at peripheral artery disease.
Rezera rebranded from NodThera earlier in 2026.
- Who
- Rezera, a biotech company formerly known as NodThera.
- What
- It has entered the queue for an initial public offering to support its NLRP3 research.
- When
- The filing was reported on October 21, 2026.
- Where
- Not stated.
- Why
- To bolster its NLRP3 research, including work related to peripheral artery disease.
This story does not have two clearly opposing sides.
NodThera rebranded as Rezera.
Rezera was reported to have entered the queue for an initial public offering.
- Company
- Rezera, formerly NodThera
- Offering
- Initial public offering
- Research target
- NLRP3
- Research duration
- A decade
- Disease focus
- Peripheral artery disease